


PHARMACEUTICAL 2018

CymaBay Therapeutics Inc. Rank 100 of 349





PHARMACEUTICAL 2018

CymaBay Therapeutics Inc. Rank 100 of 349

The relative strengths and weaknesses of CymaBay Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CymaBay Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 249% points. The greatest weakness of CymaBay Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is -30%, being 248% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	103,544
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,310
Liabilities, Non-Current	0
Other Assets	634
Other Compr. Net Income	-43
Other Expenses	1,080
Other Liabilities	2,990
Other Net Income	4,848
Property and Equipment	69
Research and Development	18,938
Revenues	0
Selling, General and Administrative Expense	12,387

Output Variable	Value in 1000 USD
Assets	104,247
Liabilities	19,300
Expenses	32,405
Stockholders Equity	84,947
Net Income	-27,557
Comprehensive Net Income	-27,578
Economic Capital Ratio	-30%